ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Live Attenuated Vaccines Market Research Report 2025
Published Date: August 2025
|
Report Code: QYRE-Auto-35K11142
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global Live Attenuated Vaccines Market Research Report 2022
BUY CHAPTERS

Global Live Attenuated Vaccines Market Research Report 2025

Code: QYRE-Auto-35K11142
Report
August 2025
Pages:86
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
GlaxoSmithKline PLC
Merck
Pfizer Inc
Astellas Pharma
Johnson & Johnson
CSL Limited
Sanofi
Serum Institute of India

Live Attenuated Vaccines Market Size

The global market for Live Attenuated Vaccines was valued at US$ 29870 million in the year 2024 and is projected to reach a revised size of US$ 44950 million by 2031, growing at a CAGR of 6.1% during the forecast period.

Live Attenuated Vaccines Market

Live Attenuated Vaccines Market

An attenuated vaccine is a vaccine created by reducing the virulence of a pathogen, but still keeping it viable (or "live"). Attenuation takes an infectious agent and alters it so that it becomes harmless or less virulent. These vaccines contrast to those produced by "killing" the virus (inactivated vaccine).
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Live Attenuated Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Live Attenuated Vaccines.
The Live Attenuated Vaccines market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Live Attenuated Vaccines market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Live Attenuated Vaccines manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Live Attenuated Vaccines Market Report

Report Metric Details
Report Name Live Attenuated Vaccines Market
Accounted market size in year US$ 29870 million
Forecasted market size in 2031 US$ 44950 million
CAGR 6.1%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Bacterial
  • Viral
Segment by Application
  • Hospitals
  • Clinics
  • Research Institutes
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company GlaxoSmithKline, Merck, Pfizer, Astellas Pharma, Johnson & Johnson, CSL, Sanofi, Serum Institute Of India
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Live Attenuated Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Live Attenuated Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Live Attenuated Vaccines Market growing?

Ans: The Live Attenuated Vaccines Market witnessing a CAGR of 6.1% during the forecast period 2025-2031.

What is the Live Attenuated Vaccines Market size in 2031?

Ans: The Live Attenuated Vaccines Market size in 2031 will be US$ 44950 million.

Who are the main players in the Live Attenuated Vaccines Market report?

Ans: The main players in the Live Attenuated Vaccines Market are GlaxoSmithKline, Merck, Pfizer, Astellas Pharma, Johnson & Johnson, CSL, Sanofi, Serum Institute Of India

What are the Application segmentation covered in the Live Attenuated Vaccines Market report?

Ans: The Applications covered in the Live Attenuated Vaccines Market report are Hospitals, Clinics, Research Institutes, Others

What are the Type segmentation covered in the Live Attenuated Vaccines Market report?

Ans: The Types covered in the Live Attenuated Vaccines Market report are Bacterial, Viral

1 Live Attenuated Vaccines Market Overview
1.1 Product Definition
1.2 Live Attenuated Vaccines by Type
1.2.1 Global Live Attenuated Vaccines Market Value Comparison by Type (2024 VS 2031)
1.2.2 Bacterial
1.2.3 Viral
1.3 Live Attenuated Vaccines by Application
1.3.1 Global Live Attenuated Vaccines Market Value by Application (2024 VS 2031)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Research Institutes
1.3.5 Others
1.4 Global Live Attenuated Vaccines Market Size Estimates and Forecasts
1.4.1 Global Live Attenuated Vaccines Revenue 2020-2031
1.4.2 Global Live Attenuated Vaccines Sales 2020-2031
1.4.3 Global Live Attenuated Vaccines Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Live Attenuated Vaccines Market Competition by Manufacturers
2.1 Global Live Attenuated Vaccines Sales Market Share by Manufacturers (2020-2025)
2.2 Global Live Attenuated Vaccines Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Live Attenuated Vaccines Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Live Attenuated Vaccines, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Live Attenuated Vaccines, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Live Attenuated Vaccines, Product Type & Application
2.7 Global Key Manufacturers of Live Attenuated Vaccines, Date of Enter into This Industry
2.8 Global Live Attenuated Vaccines Market Competitive Situation and Trends
2.8.1 Global Live Attenuated Vaccines Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Live Attenuated Vaccines Players Market Share by Revenue
2.8.3 Global Live Attenuated Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Live Attenuated Vaccines Market Scenario by Region
3.1 Global Live Attenuated Vaccines Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Live Attenuated Vaccines Sales by Region: 2020-2031
3.2.1 Global Live Attenuated Vaccines Sales by Region: 2020-2025
3.2.2 Global Live Attenuated Vaccines Sales by Region: 2026-2031
3.3 Global Live Attenuated Vaccines Revenue by Region: 2020-2031
3.3.1 Global Live Attenuated Vaccines Revenue by Region: 2020-2025
3.3.2 Global Live Attenuated Vaccines Revenue by Region: 2026-2031
3.4 North America Live Attenuated Vaccines Market Facts & Figures by Country
3.4.1 North America Live Attenuated Vaccines Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Live Attenuated Vaccines Sales by Country (2020-2031)
3.4.3 North America Live Attenuated Vaccines Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Live Attenuated Vaccines Market Facts & Figures by Country
3.5.1 Europe Live Attenuated Vaccines Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Live Attenuated Vaccines Sales by Country (2020-2031)
3.5.3 Europe Live Attenuated Vaccines Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Live Attenuated Vaccines Market Facts & Figures by Region
3.6.1 Asia Pacific Live Attenuated Vaccines Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Live Attenuated Vaccines Sales by Region (2020-2031)
3.6.3 Asia Pacific Live Attenuated Vaccines Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Live Attenuated Vaccines Market Facts & Figures by Country
3.7.1 Latin America Live Attenuated Vaccines Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Live Attenuated Vaccines Sales by Country (2020-2031)
3.7.3 Latin America Live Attenuated Vaccines Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Live Attenuated Vaccines Market Facts & Figures by Country
3.8.1 Middle East and Africa Live Attenuated Vaccines Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Live Attenuated Vaccines Sales by Country (2020-2031)
3.8.3 Middle East and Africa Live Attenuated Vaccines Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Live Attenuated Vaccines Sales by Type (2020-2031)
4.1.1 Global Live Attenuated Vaccines Sales by Type (2020-2025)
4.1.2 Global Live Attenuated Vaccines Sales by Type (2026-2031)
4.1.3 Global Live Attenuated Vaccines Sales Market Share by Type (2020-2031)
4.2 Global Live Attenuated Vaccines Revenue by Type (2020-2031)
4.2.1 Global Live Attenuated Vaccines Revenue by Type (2020-2025)
4.2.2 Global Live Attenuated Vaccines Revenue by Type (2026-2031)
4.2.3 Global Live Attenuated Vaccines Revenue Market Share by Type (2020-2031)
4.3 Global Live Attenuated Vaccines Price by Type (2020-2031)
5 Segment by Application
5.1 Global Live Attenuated Vaccines Sales by Application (2020-2031)
5.1.1 Global Live Attenuated Vaccines Sales by Application (2020-2025)
5.1.2 Global Live Attenuated Vaccines Sales by Application (2026-2031)
5.1.3 Global Live Attenuated Vaccines Sales Market Share by Application (2020-2031)
5.2 Global Live Attenuated Vaccines Revenue by Application (2020-2031)
5.2.1 Global Live Attenuated Vaccines Revenue by Application (2020-2025)
5.2.2 Global Live Attenuated Vaccines Revenue by Application (2026-2031)
5.2.3 Global Live Attenuated Vaccines Revenue Market Share by Application (2020-2031)
5.3 Global Live Attenuated Vaccines Price by Application (2020-2031)
6 Key Companies Profiled
6.1 GlaxoSmithKline
6.1.1 GlaxoSmithKline Company Information
6.1.2 GlaxoSmithKline Description and Business Overview
6.1.3 GlaxoSmithKline Live Attenuated Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.1.4 GlaxoSmithKline Live Attenuated Vaccines Product Portfolio
6.1.5 GlaxoSmithKline Recent Developments/Updates
6.2 Merck
6.2.1 Merck Company Information
6.2.2 Merck Description and Business Overview
6.2.3 Merck Live Attenuated Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Merck Live Attenuated Vaccines Product Portfolio
6.2.5 Merck Recent Developments/Updates
6.3 Pfizer
6.3.1 Pfizer Company Information
6.3.2 Pfizer Description and Business Overview
6.3.3 Pfizer Live Attenuated Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Pfizer Live Attenuated Vaccines Product Portfolio
6.3.5 Pfizer Recent Developments/Updates
6.4 Astellas Pharma
6.4.1 Astellas Pharma Company Information
6.4.2 Astellas Pharma Description and Business Overview
6.4.3 Astellas Pharma Live Attenuated Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Astellas Pharma Live Attenuated Vaccines Product Portfolio
6.4.5 Astellas Pharma Recent Developments/Updates
6.5 Johnson & Johnson
6.5.1 Johnson & Johnson Company Information
6.5.2 Johnson & Johnson Description and Business Overview
6.5.3 Johnson & Johnson Live Attenuated Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Johnson & Johnson Live Attenuated Vaccines Product Portfolio
6.5.5 Johnson & Johnson Recent Developments/Updates
6.6 CSL
6.6.1 CSL Company Information
6.6.2 CSL Description and Business Overview
6.6.3 CSL Live Attenuated Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.6.4 CSL Live Attenuated Vaccines Product Portfolio
6.6.5 CSL Recent Developments/Updates
6.7 Sanofi
6.7.1 Sanofi Company Information
6.7.2 Sanofi Description and Business Overview
6.7.3 Sanofi Live Attenuated Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Sanofi Live Attenuated Vaccines Product Portfolio
6.7.5 Sanofi Recent Developments/Updates
6.8 Serum Institute Of India
6.8.1 Serum Institute Of India Company Information
6.8.2 Serum Institute Of India Description and Business Overview
6.8.3 Serum Institute Of India Live Attenuated Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Serum Institute Of India Live Attenuated Vaccines Product Portfolio
6.8.5 Serum Institute Of India Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Live Attenuated Vaccines Industry Chain Analysis
7.2 Live Attenuated Vaccines Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Live Attenuated Vaccines Production Mode & Process Analysis
7.4 Live Attenuated Vaccines Sales and Marketing
7.4.1 Live Attenuated Vaccines Sales Channels
7.4.2 Live Attenuated Vaccines Distributors
7.5 Live Attenuated Vaccines Customer Analysis
8 Live Attenuated Vaccines Market Dynamics
8.1 Live Attenuated Vaccines Industry Trends
8.2 Live Attenuated Vaccines Market Drivers
8.3 Live Attenuated Vaccines Market Challenges
8.4 Live Attenuated Vaccines Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
GlaxoSmithKline PLC
Merck
Pfizer Inc
Astellas Pharma
Johnson & Johnson
CSL Limited
Sanofi
Serum Institute of India
List of Tables
 Table 1. Global Live Attenuated Vaccines Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Live Attenuated Vaccines Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Live Attenuated Vaccines Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Live Attenuated Vaccines Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Live Attenuated Vaccines Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Live Attenuated Vaccines Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Live Attenuated Vaccines Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Live Attenuated Vaccines Average Price (USD/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Live Attenuated Vaccines, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Live Attenuated Vaccines, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Live Attenuated Vaccines, Product Type & Application
 Table 12. Global Key Manufacturers of Live Attenuated Vaccines, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Live Attenuated Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Live Attenuated Vaccines as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Live Attenuated Vaccines Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Live Attenuated Vaccines Sales by Region (2020-2025) & (K Units)
 Table 18. Global Live Attenuated Vaccines Sales Market Share by Region (2020-2025)
 Table 19. Global Live Attenuated Vaccines Sales by Region (2026-2031) & (K Units)
 Table 20. Global Live Attenuated Vaccines Sales Market Share by Region (2026-2031)
 Table 21. Global Live Attenuated Vaccines Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Live Attenuated Vaccines Revenue Market Share by Region (2020-2025)
 Table 23. Global Live Attenuated Vaccines Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Live Attenuated Vaccines Revenue Market Share by Region (2026-2031)
 Table 25. North America Live Attenuated Vaccines Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Live Attenuated Vaccines Sales by Country (2020-2025) & (K Units)
 Table 27. North America Live Attenuated Vaccines Sales by Country (2026-2031) & (K Units)
 Table 28. North America Live Attenuated Vaccines Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Live Attenuated Vaccines Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Live Attenuated Vaccines Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Live Attenuated Vaccines Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Live Attenuated Vaccines Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Live Attenuated Vaccines Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Live Attenuated Vaccines Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Live Attenuated Vaccines Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Live Attenuated Vaccines Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Live Attenuated Vaccines Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Live Attenuated Vaccines Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Live Attenuated Vaccines Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Live Attenuated Vaccines Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Live Attenuated Vaccines Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Live Attenuated Vaccines Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Live Attenuated Vaccines Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Live Attenuated Vaccines Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Live Attenuated Vaccines Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Live Attenuated Vaccines Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Live Attenuated Vaccines Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Live Attenuated Vaccines Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Live Attenuated Vaccines Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Live Attenuated Vaccines Sales (K Units) by Type (2020-2025)
 Table 51. Global Live Attenuated Vaccines Sales (K Units) by Type (2026-2031)
 Table 52. Global Live Attenuated Vaccines Sales Market Share by Type (2020-2025)
 Table 53. Global Live Attenuated Vaccines Sales Market Share by Type (2026-2031)
 Table 54. Global Live Attenuated Vaccines Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Live Attenuated Vaccines Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Live Attenuated Vaccines Revenue Market Share by Type (2020-2025)
 Table 57. Global Live Attenuated Vaccines Revenue Market Share by Type (2026-2031)
 Table 58. Global Live Attenuated Vaccines Price (USD/Unit) by Type (2020-2025)
 Table 59. Global Live Attenuated Vaccines Price (USD/Unit) by Type (2026-2031)
 Table 60. Global Live Attenuated Vaccines Sales (K Units) by Application (2020-2025)
 Table 61. Global Live Attenuated Vaccines Sales (K Units) by Application (2026-2031)
 Table 62. Global Live Attenuated Vaccines Sales Market Share by Application (2020-2025)
 Table 63. Global Live Attenuated Vaccines Sales Market Share by Application (2026-2031)
 Table 64. Global Live Attenuated Vaccines Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Live Attenuated Vaccines Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Live Attenuated Vaccines Revenue Market Share by Application (2020-2025)
 Table 67. Global Live Attenuated Vaccines Revenue Market Share by Application (2026-2031)
 Table 68. Global Live Attenuated Vaccines Price (USD/Unit) by Application (2020-2025)
 Table 69. Global Live Attenuated Vaccines Price (USD/Unit) by Application (2026-2031)
 Table 70. GlaxoSmithKline Company Information
 Table 71. GlaxoSmithKline Description and Business Overview
 Table 72. GlaxoSmithKline Live Attenuated Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 73. GlaxoSmithKline Live Attenuated Vaccines Product
 Table 74. GlaxoSmithKline Recent Developments/Updates
 Table 75. Merck Company Information
 Table 76. Merck Description and Business Overview
 Table 77. Merck Live Attenuated Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 78. Merck Live Attenuated Vaccines Product
 Table 79. Merck Recent Developments/Updates
 Table 80. Pfizer Company Information
 Table 81. Pfizer Description and Business Overview
 Table 82. Pfizer Live Attenuated Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 83. Pfizer Live Attenuated Vaccines Product
 Table 84. Pfizer Recent Developments/Updates
 Table 85. Astellas Pharma Company Information
 Table 86. Astellas Pharma Description and Business Overview
 Table 87. Astellas Pharma Live Attenuated Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 88. Astellas Pharma Live Attenuated Vaccines Product
 Table 89. Astellas Pharma Recent Developments/Updates
 Table 90. Johnson & Johnson Company Information
 Table 91. Johnson & Johnson Description and Business Overview
 Table 92. Johnson & Johnson Live Attenuated Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 93. Johnson & Johnson Live Attenuated Vaccines Product
 Table 94. Johnson & Johnson Recent Developments/Updates
 Table 95. CSL Company Information
 Table 96. CSL Description and Business Overview
 Table 97. CSL Live Attenuated Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 98. CSL Live Attenuated Vaccines Product
 Table 99. CSL Recent Developments/Updates
 Table 100. Sanofi Company Information
 Table 101. Sanofi Description and Business Overview
 Table 102. Sanofi Live Attenuated Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 103. Sanofi Live Attenuated Vaccines Product
 Table 104. Sanofi Recent Developments/Updates
 Table 105. Serum Institute Of India Company Information
 Table 106. Serum Institute Of India Description and Business Overview
 Table 107. Serum Institute Of India Live Attenuated Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 108. Serum Institute Of India Live Attenuated Vaccines Product
 Table 109. Serum Institute Of India Recent Developments/Updates
 Table 110. Key Raw Materials Lists
 Table 111. Raw Materials Key Suppliers Lists
 Table 112. Live Attenuated Vaccines Distributors List
 Table 113. Live Attenuated Vaccines Customers List
 Table 114. Live Attenuated Vaccines Market Trends
 Table 115. Live Attenuated Vaccines Market Drivers
 Table 116. Live Attenuated Vaccines Market Challenges
 Table 117. Live Attenuated Vaccines Market Restraints
 Table 118. Research Programs/Design for This Report
 Table 119. Key Data Information from Secondary Sources
 Table 120. Key Data Information from Primary Sources
 Table 121. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Live Attenuated Vaccines
 Figure 2. Global Live Attenuated Vaccines Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Live Attenuated Vaccines Market Share by Type: 2024 & 2031
 Figure 4. Bacterial Product Picture
 Figure 5. Viral Product Picture
 Figure 6. Global Live Attenuated Vaccines Market Value by Application (2020-2031) & (US$ Million)
 Figure 7. Global Live Attenuated Vaccines Market Share by Application: 2024 & 2031
 Figure 8. Hospitals
 Figure 9. Clinics
 Figure 10. Research Institutes
 Figure 11. Others
 Figure 12. Global Live Attenuated Vaccines Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 13. Global Live Attenuated Vaccines Market Size (2020-2031) & (US$ Million)
 Figure 14. Global Live Attenuated Vaccines Sales (2020-2031) & (K Units)
 Figure 15. Global Live Attenuated Vaccines Average Price (USD/Unit) & (2020-2031)
 Figure 16. Live Attenuated Vaccines Report Years Considered
 Figure 17. Live Attenuated Vaccines Sales Share by Manufacturers in 2024
 Figure 18. Global Live Attenuated Vaccines Revenue Share by Manufacturers in 2024
 Figure 19. Global 5 and 10 Largest Live Attenuated Vaccines Players: Market Share by Revenue in Live Attenuated Vaccines in 2024
 Figure 20. Live Attenuated Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 21. Global Live Attenuated Vaccines Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 22. North America Live Attenuated Vaccines Sales Market Share by Country (2020-2031)
 Figure 23. North America Live Attenuated Vaccines Revenue Market Share by Country (2020-2031)
 Figure 24. U.S. Live Attenuated Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Canada Live Attenuated Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 26. Europe Live Attenuated Vaccines Sales Market Share by Country (2020-2031)
 Figure 27. Europe Live Attenuated Vaccines Revenue Market Share by Country (2020-2031)
 Figure 28. Germany Live Attenuated Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. France Live Attenuated Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. U.K. Live Attenuated Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Italy Live Attenuated Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Russia Live Attenuated Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Asia Pacific Live Attenuated Vaccines Sales Market Share by Region (2020-2031)
 Figure 34. Asia Pacific Live Attenuated Vaccines Revenue Market Share by Region (2020-2031)
 Figure 35. China Live Attenuated Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Japan Live Attenuated Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. South Korea Live Attenuated Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. India Live Attenuated Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Australia Live Attenuated Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Taiwan Live Attenuated Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Indonesia Live Attenuated Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Thailand Live Attenuated Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Malaysia Live Attenuated Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Philippines Live Attenuated Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Latin America Live Attenuated Vaccines Sales Market Share by Country (2020-2031)
 Figure 46. Latin America Live Attenuated Vaccines Revenue Market Share by Country (2020-2031)
 Figure 47. Mexico Live Attenuated Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Brazil Live Attenuated Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Argentina Live Attenuated Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Middle East and Africa Live Attenuated Vaccines Sales Market Share by Country (2020-2031)
 Figure 51. Middle East and Africa Live Attenuated Vaccines Revenue Market Share by Country (2020-2031)
 Figure 52. Turkey Live Attenuated Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Saudi Arabia Live Attenuated Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. U.A.E Live Attenuated Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 55. Global Sales Market Share of Live Attenuated Vaccines by Type (2020-2031)
 Figure 56. Global Revenue Market Share of Live Attenuated Vaccines by Type (2020-2031)
 Figure 57. Global Live Attenuated Vaccines Price (USD/Unit) by Type (2020-2031)
 Figure 58. Global Sales Market Share of Live Attenuated Vaccines by Application (2020-2031)
 Figure 59. Global Revenue Market Share of Live Attenuated Vaccines by Application (2020-2031)
 Figure 60. Global Live Attenuated Vaccines Price (USD/Unit) by Application (2020-2031)
 Figure 61. Live Attenuated Vaccines Value Chain
 Figure 62. Channels of Distribution (Direct Vs Distribution)
 Figure 63. Bottom-up and Top-down Approaches for This Report
 Figure 64. Data Triangulation
 Figure 65. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SecuX Technology Inc

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions